Craft

Catalent

Stock Price

$56.7

2024-02-09

Market Capitalization

$10.2 B

2024-02-09

Revenue

$4.3 B

FY, 2023

Catalent Summary

Company Summary

Overview
Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. It operates through two segments: Biologics, and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins, cell, gene, and other nucleic acid therapies, induced pluripotent stem cells, oncolytic viruses, vaccines, etc. The Pharma and Consumer Health segment specializes in oral solids, soft gel formulations, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
Type
Public
Status
Active
Founded
2007
HQ
Somerset, NJ, US | view all locations
Website
https://www.catalent.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Alessandro Maselli

    Alessandro Maselli, President, Chief Executive Officer, and Board Member

  • Charles Lickfold

    Charles Lickfold, Senior Vice President & Chief Information Officer

  • Lisa Evoli

    Lisa Evoli, Senior Vice President & Chief Human Resources Officer

  • Joseph A. Ferraro

    Joseph A. Ferraro, Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Operating MetricsView all

Products

8K

FY, 2023

Doses Produced Yearly

70B
12.5%

FY, 2023

Customers

1.2K

FY, 2023

LocationsView all

51 locations detected

  • Somerset, NJ HQ

    United States

    14 School House Rd

  • Baltimore, MD

    United States

    801 W Baltimore St Suite 302

  • Bloomington, IN

    United States

    1300 S Patterson Dr

  • Bloomington, IN

    United States

    3770 Jonathan Dr

  • Bristow, VA

    United States

    7370 Merritt Pk Dr Unit 110

  • Chelsea, MA

    United States

    190 Everett Ave

and 45 others

Catalent Financials

Summary Financials

Revenue (Q1, 2024)
$982.0M
Gross profit (Q1, 2024)
$169.0M
Net income (Q1, 2024)
($759.0M)
Cash (Q1, 2024)
$209.0M
EBIT (Q1, 2024)
($726.0M)
Enterprise value
$15.0B

Footer menu